KLK3 and prostate carcinoma: The primary clinical significance of the present data was the discovery showing that RP was the treatment option for patients with high-grade, but low-PSA, prostate cancer, while EBRT+BT is an alternative option for the treatment of patients with an age of >70 years old, or a PSA level of ≤2.5 ng/ml.